Form 4: Lyell Immunopharma Director Hans Bishop Acquires 130,000 Stock Options

Director Hans Bishop reports the acquisition of 130,000 stock options in Lyell Immunopharma, Inc.

Summary

• Hans Edgar Bishop, a director of Lyell Immunopharma, Inc., filed a Form 4 disclosing a transaction.
• On June 14, 2024, Bishop acquired 130,000 stock options with an exercise price of $2.36.
• These options vest on the earlier of the next annual stockholder meeting following June 14, 2024, or the first anniversary of that date, contingent upon continuous service.
• Bishop directly owns 4,685,614 shares of common stock.
• Matthew Lang, as Attorney-in-Fact, signed the report on June 17, 2024.
• A Power of Attorney document grants Matthew Lang, Charles Newton, Hector Casab, Anitha Anne, and Allison Peth the authority to execute Forms 3, 4, and 5 on Bishop's behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continuous service and will occur either at the next annual meeting or on the first anniversary of the grant date.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options extensively to align the interests of their leadership with those of shareholders.
• The vesting schedules and exercise prices are generally structured to incentivize long-term value creation.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates